Recovery ⏱ Half-life: ~23-30 days (depot)

Lanreotide

Lanreotide (Somatuline Depot)

Buy at SourcePeptides →
Half-Life
~23-30 days (depot)
Purity
Pharmaceutical grade
Mol. Weight
1,096.3 Da
Form
Pre-filled syringe for deep subcutaneous injection

What is Lanreotide?

Lanreotide (Somatuline Depot) is a somatostatin analog used for acromegaly and gastroenteropancreatic neuroendocrine tumors. Its unique supersaturated solution technology allows once-monthly deep subcutaneous injection with self-administration capability, offering a practical advantage over intramuscular octreotide LAR which requires healthcare provider administration.

Dosage Information (Research Use)

Acromegaly: 60-120mg deep SC every 4 weeks. GEP-NET: 120mg every 4 weeks. Prescription medication.

Reconstitution & Handling

Pre-filled syringe — no reconstitution.

Half-Life & Pharmacokinetics

~23-30 days (depot)

Reported Observations in Literature

Diarrhea (37-65%), abdominal pain (7-19%), cholelithiasis/gallstones (14-20%), injection site reactions, hyperglycemia (7%). Gallbladder monitoring recommended.

Key Research References

  • Caplin ME et al. “Lanreotide in metastatic GEP-NET (CLARINET).” N Engl J Med. 2014;371:224-33

How Lanreotide Works

Lanreotide is a cyclic octapeptide analog of somatostatin with preferential affinity for SSTR2 and SSTR5 receptors. It inhibits growth hormone secretion from the pituitary, reduces IGF-1 levels, and has antiproliferative effects on neuroendocrine tumor cells. The depot formulation forms a solid gel at the injection site that slowly releases drug over 4 weeks.

Research Applications

🔬 Acromegaly treatment
🔬 Neuroendocrine tumors
🔬 Carcinoid syndrome

Research Findings

The CLARINET trial demonstrated tumor growth control in 65.1% of patients with GEP-NET over 96 weeks, compared to 33% with placebo (HR 0.47). Self-injection feasibility confirmed in the ADVOCAT study. FDA-approved for acromegaly (2007) and GEP-NET (2014).

Dosage & Administration

Acromegaly: 60-120mg deep SC every 4 weeks. GEP-NET: 120mg every 4 weeks. Prescription medication.

Safety & Side Effects

Diarrhea (37-65%), abdominal pain (7-19%), cholelithiasis/gallstones (14-20%), injection site reactions, hyperglycemia (7%). Gallbladder monitoring recommended.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
Molecular Weight 1,096.3 Da
Half-Life ~23-30 days (depot)
Purity Pharmaceutical grade
Form Pre-filled syringe for deep subcutaneous injection
Storage Room temperature up to 25°C for up to 4 weeks.

Key Research References

  • Caplin ME et al. "Lanreotide in metastatic GEP-NET (CLARINET)." N Engl J Med. 2014;371:224-33

Get Lanreotide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Recovery
Synthetic fragment of thymosin beta-4 researched for wound healing, cellular migration, and anti-inflammatory activity.
Recovery
Synthetic somatostatin analog used to treat acromegaly, carcinoid tumors, and severe diarrhea — a cornerstone peptide drug in…
Recovery
Thymic peptide with potent immunomodulatory properties, approved in multiple countries for viral hepatitis and as an immune adjuvant.